



FRIENDS
OF THE GLOBAL FIGHT

AGAINST AIDS,
TUBERCULOSIS
AND MALARIA

INNOVATION

TO END THE HIV, TB AND MALARIA EPIDEMICS

Our recent report explores how new approaches and groundbreaking innovations in the fight against HIV, TB and malaria—such as genetic engineering and rapid, point-of-care diagnostics—are improving disease surveillance and transforming how these diseases are prevented, diagnosed and treated.

HIV/AIDS

For HIV, long-acting injectables, including FDA-approved **cabotegravir and lenacapavir**, are redefining care by offering sustained viral suppression with much less frequent dosing, e.g. every six months.



TUBERCULOSIS

Cutting-edge technologies such as **CRISPR-based TB detection** are emerging as highly sensitive and cost-effective diagnostics while **shorter, more effective regimens** are helping streamline treatment.



MALARIA

Dual-active ingredient bed nets, automated AI-powered microscopes, new antimalarial compounds and resistance-proof combinations are transforming the fight against malaria.



Self-testing is a critical tool for diagnosing and treating HIV. The private sector is helping increase its availability:

Smart phones: The SMARTtest app makes HIV testing more portable, affordable, and accessible, especially in areas with limited healthcare infrastructure. By using a dongle connected to a phone, combined with an existing blood-based rapid HIV and syphilis test (the INSTI Multiplex®), individuals can learn [their HIV status] within one minute.



REPORT RECOMMENDATIONS

Engage a broad set of stakeholders—at the local and global level, as well as in the private sector—in the identification, scale-up and utilization of innovations.

Ensure that communities lead the way—the private sector should scale up work with communities to develop, deploy and build demand for innovations.

Facilitate multisectoral approaches to developing new technical solutions.

Incentivize the private sector to develop new and innovative approaches to addressing global health challenges.

Fully fund the Global Fund for optimum impact in incentivizing innovation, bringing new technologies to market and accelerating an end to three epidemics.

MARKET SHAPING

The Global Fund's Role in Increasing Access to Innovative Healthcare

Using an approach known as market shaping, the Global Fund fosters partnerships with countries, funders and product developers to remove market barriers, increase access to life-saving tools and incentivize more innovation—all while cutting costs and increasing efficiency.



Affordability and pricing models

Purchasing power and commitments


Demand creation

Adapting delivery and access systems

Driving next generation innovation

Example of the Global Fund's market shaping efforts:

TID (Tenofovir/lamivudine/Dolutegravir), an HIV medication which rapidly suppresses the virus and has few side effects and a high barrier to resistance.



Partner-centered model

The Global Fund and its partners—including Unitaid, CHAI, WHO, and PEPFAR—radically reshaped the market for TLD by:

- **Pooling orders across countries** to lower prices through higher purchase volumes
- **Negotiating a 'ceiling price'** or maximum price suppliers could charge
- **Enabling generic manufacturers** to join the market through licensing agreements



Country priority focus

- **Accelerated introduction** of new regimen at unprecedented scale
- **Achieved price reductions to ≤\$40 per person per year**, a reduction from the 2017 ceiling price of \$75
- **Tripled the number of suppliers** for first-line HIV treatments to increase supply security and price competition



Scale innovations rapidly

The proportion of adults taking dolutegravir-based regimens rose from 2% to 91% in five years

